Linzagolix - Kissei Pharmaceutical/ObsEva

Drug Profile

Linzagolix - Kissei Pharmaceutical/ObsEva

Alternative Names: KLH-2109; OBE-2109

Latest Information Update: 05 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Kissei Pharmaceutical
  • Developer Kissei Pharmaceutical; ObsEva
  • Class 2 ring heterocyclic compounds; Antihormones; Pyrimidines; Thiophenes
  • Mechanism of Action LHRH receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Uterine leiomyoma
  • Phase II Adenomyosis; Endometriosis

Most Recent Events

  • 28 Sep 2018 Additional safety and efficacy data from the phase IIb EDELWEISS trial in Endometriosis associated pelvic pain released by ObsEva
  • 28 Sep 2018 ObsEva plans a phase III trial for Endometriosis in early 2019
  • 28 Jun 2018 Chemical structure information added
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top